Key Points As several mechanisms lead to -cell failure in type 1 diabetes mellitus (T1DM), strategies combining different molecules could target different pathways involved in the pathogenesis of T1DM Different combination therapies have been tested in preclinical studies with encouraging results, but results from clinical trials have not matched expectations Heterogeneity in the age of patients with T1DM and the low rate of human -cell regeneration are possible explanations for the negative results of clinical trials that should be addressed in future studies Proton pump inhibitors and incretin-based agents can stimulate -cell regeneration, so future trials in patients with T1DM should investigate their potential in combination with immunomodulatory compounds The issue of patient heterogeneity can be addressed by designing trials evaluating the relative effectiveness of interventions in specific subgroups of patients Abstract Immunotherapies for type 1 diabetes mellitus (T1DM) have been the focus of intense basic and clinical research over the past few decades
Gastric emptying breath test For this test, you eat a meal that contains a substance that is absorbed in your intestines and eventually passed into your breath
Copper peptides target the hair follicle and scalp, not the hair shaft where colour molecules are deposited
Newer research is looking at how the anti-inflammatory effects of these drugs might be helpful to people living with neurodegenerative diseases, such as Alzheimers and Parkinsons
and common synthetic antioxidants such as butyl hydroxybenzoate (BHA), butylated hydroxytoluene (BHT), EDTA, etc
